alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1998
<PERIOD-END>                               DEC-31-1997
<CASH>                                          66,593
<SECURITIES>                                         0
<RECEIVABLES>                                  471,641
<ALLOWANCES>                                    71,193
<INVENTORY>                                     27,752
<CURRENT-ASSETS>                               599,291
<PP&E>                                         717,232
<DEPRECIATION>                                 217,174
<TOTAL-ASSETS>                               1,788,365
<CURRENT-LIABILITIES>                          323,374
<BONDS>                                      1,286,876
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           411
<OTHER-SE>                                      62,182
<TOTAL-LIABILITY-AND-EQUITY>                 1,788,365
<SALES>                                        421,606
<TOTAL-REVENUES>                               421,606
<CGS>                                                0
<TOTAL-COSTS>                                  475,129
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              19,328
<INCOME-PRETAX>                               (72,851)
<INCOME-TAX>                                  (17,699)
<INCOME-CONTINUING>                           (55,324)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                               (11,275)
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-PRIMARY>                                   (1.40)
<EPS-DILUTED>                                   (1.40)
        

</TABLE>
EXHIBIT 99.2
                                  ------------

     CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
                                   SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002
                        ---------------------------------

The undersigned hereby certifies,  pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (18 U.S.C. 1350), that, to the best of my knowledge:

1.   The Quarterly Report on Form 10-Q of Cumberland Technologies,  Inc. for the
     period ended March 31, 2003 as filed May 30, 2003 with the  Securities  and
     Exchange Commission,  fully complies with the requirements of Section 13(a)
     or 15(d) of the Securities Exchange Act of 1934; and

2.   The information  contained in the quarterly report fairly presents,  in all
     material  respects,  the  financial  condition and results of operations of
     Cumberland Technologies, Inc.




Dated:  May 30, 2003                     By: /s/  Carol S. Black
                                         ---------------------------------------
                                         Carol S. Black, Chief Financial Officer
                                         of Cumberland Technologies, Inc.
IN THE SUPREME COURT OF PENNSYLVANIA

IN RE:

APPOINTMENT TO CONTINUING 

JUDICIAL EDUCATION BOARD OF 

JUDGES

:

:

:

:

:

:

NO. 955

SUPREME COURT RULES DOCKET 

ORDER

PER CURIAM

AND NOW, this 21st of July, 2023, the Honorable Maria C. McLaughlin, 

Philadelphia, is hereby appointed to the Continuing Judicial Education Board of Judges

for a term expiring December 31, 2024.
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 20
- 0494 STATE OF MONTANA,

Plaintiff and Appellee, v. DAVID ALAN SPAGNOLO ,

Defendant and Appellant.

**ORDER** Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an extension of time to and including March 2 , 2021 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

January 26 2021

01/26/2021

Case Number: DA 20-0494
EXHIBIT 11


                       UNITED SHIPPING & TECHNOLOGY, INC.
                    COMPUTATION OF NET LOSS PER COMMON SHARE

<TABLE>
<CAPTION>
                                                        For the Year Ended June 30,
                                                            1999            1998
                                                        -----------     -----------
<S>                                                       <C>             <C>
Weighted average number of issued shares outstanding      6,881,764       4,977,469

Shares outstanding used to compute net loss per share     6,881,764       4,977,469
                                                        ===========     ===========

Net Loss                                                $(2,894,479)    $(1,901,130)
                                                        ===========     ===========

Net Loss Per Common Share, basic and diluted                 ($0.42)         ($0.38)
                                                        ===========     ===========
</TABLE>
Jean CHAMBERS, Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D17-4712

District Court of Appeal of Florida, Second District.

February 01, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
Sorina Maria Suma CHRISTIAN v. Alan Cameron CHRISTIAN

2160029

Court of Civil Appeals of Alabama.

March 7, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
1 SUPREME COURT OF THE STATE OF MONTANA
DA 21
- 0603 NORVAL ELECTRIC COOPERATIVE INC., Appellant /Cross

- Appellee

v. SHALAINE LAWSON, Appellee /Cross

- Appellant

____________________________ PROPOSED ORDER ON APP ELLEE / CROSS
- APPELLANT’S UNOPPOSED MOTION TO SUSPEND DUE DATE FOR COMBINED

RESPONSE AND CROSS
- APPEAL UNTIL COURT’S RECORD IS COMPLETE

____________________________ Upon consideration of Appellee/Cross

- Appellant ’s unopposed motion to suspend the due date for her combined response and cross

- appeal until this Court’s record is complete , and good cause appearing therefor, IT IS HEREBY ORDERED that the April 25, 2022 , due date for Appellee/Cross

- Appellant ’s combined response and cross

- appeal is suspended and that said brief will be due within 30 days of this Court’s receiving the boxes of file materials from the Valley County Clerk of Court and filing said information into this Court’s record.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

April 7 2022

04/07/2022

Case Number: DA 21-0603
January 4, 2019
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AT MARCH 31, 1997 (UNAUDITED) AND CONSOLIDATED
INCOME STATEMENT FOR THE THREE MONTHS ENDED MARCH 31, 1997 (UNAUDITED) AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          17,709
<SECURITIES>                                         0
<RECEIVABLES>                                  439,422
<ALLOWANCES>                                    72,379
<INVENTORY>                                     57,907
<CURRENT-ASSETS>                               497,949
<PP&E>                                         651,300
<DEPRECIATION>                                 320,797
<TOTAL-ASSETS>                               1,142,732
<CURRENT-LIABILITIES>                          161,640
<BONDS>                                        614,175
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            51
<OTHER-SE>                                     364,171
<TOTAL-LIABILITY-AND-EQUITY>                 1,142,732
<SALES>                                        313,863
<TOTAL-REVENUES>                               313,863
<CGS>                                          104,679
<TOTAL-COSTS>                                  104,679
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                15,764
<INTEREST-EXPENSE>                              12,759
<INCOME-PRETAX>                                 29,151
<INCOME-TAX>                                     9,911
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    19,240
<EPS-PRIMARY>                                      .37
<EPS-DILUTED>                                      .37
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
         This schedule  contains  information  derived from the financial tables
         attached  to the  Company's  Report  on Form 10Q for the  period  ended
         September 30, 1999.
</LEGEND>
<CIK>                           0000881695
<NAME>                          Palomar Medical Technologies, Inc.


<S>                                        <C>
<PERIOD-TYPE>                              9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       8,557,690
<SECURITIES>                                20,517,171
<RECEIVABLES>                                2,881,757
<ALLOWANCES>                                   650,000
<INVENTORY>                                  4,131,854
<CURRENT-ASSETS>                            39,706,640
<PP&E>                                       5,564,520
<DEPRECIATION>                               4,252,951
<TOTAL-ASSETS>                              41,910,495
<CURRENT-LIABILITIES>                       16,233,126
<BONDS>                                      2,744,016
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                         60
<COMMON>                                       110,345
<OTHER-SE>                                  22,822,948
<TOTAL-LIABILITY-AND-EQUITY>                41,910,495
<SALES>                                     20,074,303
<TOTAL-REVENUES>                            21,931,126
<CGS>                                       10,991,486
<TOTAL-COSTS>                               11,734,235
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             546,173
<INCOME-PRETAX>                             33,569,117
<INCOME-TAX>                                 2,500,000
<INCOME-CONTINUING>                         31,069,117
<DISCONTINUED>                               (435,000)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                30,643,117
<EPS-BASIC>                                       2.98
<EPS-DILUTED>                                     2.81



</TABLE>
Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February 19, 2009



 Exhibit 4.10 
 AMENDMENT NO. 1 TO WARRANT 
 TO 
 PURCHASE COMMON STOCK 
 THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK (this “Amendment”) is entered into as of the 19th day of February
2009, by and between ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) and Boulder Ventures IV (Annex), L.P. 
 Recitals

 A. The Holder was previously issued a Warrant to Purchase Common Stock dated as of October 10, 2008 (the “Warrant”).
Capitalized terms used in this Amendment, but not otherwise defined in this Amendment, shall have the meanings assigned to them in the Warrant. 
 B. The
Holder and ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) desire to amend the Warrant to reflect the closing of the Merger and the exchange of the common stock of the Corporation (as defined below) for the common stock of ARCA
biopharma Colorado, Inc., a Delaware corporation (f/k/a ARCA biopharma, Inc.) in connection with such closing. 
 Amendments 

 1. The definition of the term “Exercise Price” in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the
following: 
 “(b) “Exercise Price” shall mean $9.7406, subject to adjustment pursuant to the terms of the
Warrant, including Section 5 of the Warrant.” 
 2. The definition of the term “Exercise Shares” in Section 1(c) of the Warrant
shall be deleted in its entirety and replaced with the following: 
 “(c) “Exercise Shares” shall mean 28,651
shares of common stock of the Corporation (the “Common Stock”) issuable upon the exercise of the Warrant, subject to adjustment pursuant to the terms of the Warrant, including Section 5 of the Warrant.” 
 3. The following defined term shall be added to Section 1 of the Warrant: 
 “(e) “Corporation” shall mean ARCA biopharma, Inc. a Delaware corporation (f/k/a Nuvelo, Inc.).” 
 4. Except for revisions expressly set forth in this Amendment, the parties hereby ratify and confirm the terms of the Warrant in their entirety. 







 IN WITNESS WHEREOF, the undersigned have executed this Amendment to be effective as of the date first set
forth above. 
  

									
	Corporation:	 		 	Holder:
			
	ARCA BIOPHARMA, INC.	 		 	Boulder Ventures IV (Annex), L.P.
			
		 		 	By:  BV Partners IV, L.L.C., its General Partner
					
	By:	 	/s/ Christopher D. Ozeroff	 		 	By:	 	/s/ Kyle Lefkoff
		 	 Christopher D. Ozeroff, Executive Vice
 of Business
Development and General Counsel
	 		 	 Print Name: Kyle Lefkoff
 Title: Managing
Member
<PAGE>


                                                                    Exhibit 99.2



                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



         In connection with the Quarterly Report of Metretek Technologies, Inc.
(the "Company") on Form 10-QSB for the quarterly period ended September 30,
2002, as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, A. Bradley Gabbard, Chief Financial Officer of the Company,
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:

         1.       The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         2.       The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.



                                         /s/  A. Bradley Gabbard
                                         ------------------------------------


                                         A. Bradley Gabbard
                                         Chief Financial Officer
                                         November 12, 2002
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Foundation on the Arts and the Humanities

###### National Endowment for the Arts

# AGENCY:

National Endowment for the Arts, National Foundation on the Arts and the Humanities.

# ACTION:

Notice of meeting.

# SUMMARY:

Pursuant to the Federal Advisory Committee Act, as amended, notice is hereby given that 1 meeting of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference or videoconference.

# DATES:

                        See the                         **SUPPLEMENTARY INFORMATION**                         section for individual meeting times and dates. All meetings are Eastern time and ending times are approximate:                    

# ADDRESSES:

National Endowment for the Arts, Constitution Center, 400 7th St. SW, Washington, DC 20506.

# FOR FURTHER INFORMATION CONTACT:

                        Further information with reference to these meetings can be obtained from Ms. Sherry Hale, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, DC 20506;                         *hales@arts.gov,*                         or call 202/682-5696.                    

# SUPPLEMENTARY INFORMATION:

The closed portions of meetings are for the purpose of Panel review, discussion, evaluation, and recommendations on financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency. In accordance with the determination of the Chairman of September 10, 2019, these sessions will be closed to the public pursuant to subsection (c)(6) of section 552b of title 5, United States Code.

The upcoming meeting is: 

American Rescue Plan (ARP) Orgs Deadline Extension Panel (review of applications): This meeting will be closed.

*Date and time:*                     February 16, 2022, 1:00 p.m. to 3:00 p.m.                

Dated: January 26, 2022.

Sherry Hale,

Staff Assistant, National Endowment for the Arts.

[FR Doc. 2022-01930 Filed 1-28-22; 8:45 am]

BILLING CODE 7537-01-P
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Con. Res. 27 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
117th CONGRESS
  1st Session
H. CON. RES. 27

_______________________________________________________________________

                         CONCURRENT RESOLUTION

    Resolved by the House of Representatives (the Senate concurring), 
That the remains of the late United States Capitol Police Officer 
William F. Evans shall be permitted to lie in honor in the rotunda of 
the Capitol on April 13, 2021, and the Architect of the Capitol, under 
the direction of the Speaker of the House of Representatives and the 
President pro tempore of the Senate,

              

 shall take all necessary steps for the accomplishment of that purpose.

            Passed the House of Representatives April 8, 2021.

            Attest:

                                                                 Clerk.
117th CONGRESS

  1st Session

                            H. CON. RES. 27

_______________________________________________________________________

                         CONCURRENT RESOLUTION

Permitting the remains of the late United States Capitol Police Officer 
    William F. Evans to lie in honor in the rotunda of the Capitol.
```
M.D., Mother of L.G., Minor Child, Appellant, v. DEPARTMENT OF CHILDREN AND FAMILIES, Appellee.

No. 1D17-4508

District Court of Appeal of Florida, First District.

February 7, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
IN THE UNITED STATES DISTRICT COURT

FOR THE SOUTHERN DISTRICT OF OHIO

WESTERN DIVISION AT DAYTON

GREGORY G. WHITE, : Case No. 3:18-cv-289

:

Petitioner, : Judge Thomas M. Rose

 :

v. :

: 

NORMAN ROBINSON, Warden, :

London Correctional Institution, :

:

Respondent. :

______________________________________________________________________________

ENTRY AND ORDER OVERRULING OBJECTIONS (DOCS. 8, 9, 14, 17, 18); 

ADOPTING SUPPLEMENTAL REPORT AND RECOMMENDATIONS (DOC. 11)

AND SECOND SUPPLEMENTAL REPORT AND RECOMMENDATIONS

(DOC. 16); AND TRANSFERRING CASE TO THE SIXTH CIRCUIT FOR 

CONSIDERATION UNDER 28 U.S.C. § 2244(b)

______________________________________________________________________________

This habeas corpus action is before the Court on Petitioner Gregory G. White’s Objections 

(Docs. 8, 9, 14, 17, 18) to Magistrate Judge Michael R. Merz’s Transfer Order (Doc. 7), 

Supplemental Report and Recommendations (Doc. 11), and Second Supplemental Report and 

Recommendations (Doc. 16). Magistrate Judge Merz recommended that the Court order the Clerk 

to transfer this case to the Sixth Circuit under 28 U.S.C. § 2244(b) to determine whether it may 

proceed. White objected to Magistrate Judge Merz’s transfer recommendation, as set forth in his 

entries in this matter. This matter is now ripe for the Court’s review. 

As required by 28 U.S.C. § 636(b) and Federal Rule of Civil Procedure 72(b), the Court 

has made a de novo review of the record in this case. Upon said review, the Court finds that 

White’s Objections (Docs. 8, 9, 14, 17, 18) are not well-taken and they are hereby OVERRULED. 

The Court ADOPTS the Supplemental Report and Recommendations (Doc. 11) and Second 

Supplemental Report and Recommendations (Doc. 16) in their entirety. Accordingly, the Clerk is 
2

ordered to TRANSFER this case to the Sixth Circuit under 28 U.S.C. § 2244(b) for its 

determination of whether it may proceed.

DONE and ORDERED in Dayton, Ohio, this Wednesday, November 7, 2018. 

 s/Thomas M. Rose

________________________________

THOMAS M. ROSE

 UNITED STATES DISTRICT JUDGE
Case: 2:18-cv-00966-EAS-EPD Doc #: 28 Filed: 10/04/18 Page: 1 of 1  PAGEID #: 177
<PAGE>   1
                                                                    EXHIBIT 11.1


                             CHEMTRAK INCORPORATED

                     COMPUTATION OF INCOME (LOSS) PER SHARE






<TABLE>
<CAPTION>
                                                           Three months ended                            Nine months ended
                                                             September 30,                               September 30,
                                                ------------------------------------       ---------------------------------------
                                                     1996                   1995                  1996                   1995
                                                ------------            ------------          ------------            ------------ 
<S>                                            <C>                      <C>                   <C>                     <C>
Weighted average common shares outstanding        10,192,000               9,699,000             9,808,000               9,624,000
                                                ============            ============          ============            ============ 
Net Income (loss)                               $ (1,868,000)           $ (1,241,000)         $ (5,497,000)           $ (4,723,000)
                                                ============            ============          ============            ============ 
Net Income (loss) per share                     $      (0.18)           $      (0.13)         $      (0.56)           $      (0.49)
                                                ============            ============          ============            ============ 
</TABLE>
















                                       13